Release of different Amphotericin B (cas 1397-89-3) formulations from PMMA bone cements and their activity against Candida biofilm

Add time:09/04/2019    Source:sciencedirect.com

Amphotericin B (cas 1397-89-3) is used for local delivery from polymethylmethacrylate to treat fungal prosthetic joint infections. The optimal amphotericin B formulation and the influence of different poragens in the bone cements are unknown. To investigate the necessary amount of amphotericin B in the bone cement to prevent Candida biofilm several amphotericin B formulations were studied: non-liposomal and liposomal with or without poragen gentamicin. For the non-liposomal formulation, standard bile salt, the sodium deoxycholate, was used and additionally N-methyl-D-glucamine/palmitate was applied. The activity of the released amphotericin B was tested against C. albicans, C. glabrata, C. parapsilosis and C. krusei biofilms with application of the isothermal calorimeter and standard microbiological methods. Compressive strength was measured before and after antifungal elution from the cements. There is less aggregated N-methyl-D-glucamine/palmitate amphotericin B released but its antifungal activity is equivalent with the deoxycholate amphotericin B. The minimum quantity of antifungal preventing the Candida biofilm formation is 12.5 mg in gram of polymer powder for both non-liposomal formulations. The addition of gentamicin reduced the release of sodium deoxycholate amphotericin B. Gentamicin can be added to N-methyl-D-glucamine/palmitate amphotericin B in order to boost the antifungal release. When using liposomal amphotericin B more drug is released. All amphotericin B formulations were active against Candida biofilms. Although compressive strength slightly decreased, the obtained values were above the level of strength recommended for the implant fixation. The finding of this work might be beneficial for the treatment of the prosthetic joint infections caused by Candida spp.

We also recommend Trading Suppliers and Manufacturers of Amphotericin B (cas 1397-89-3). Pls Click Website Link as below: cas 1397-89-3 suppliers

Prev:In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B (cas 1397-89-3) formulations: Heated Amphotericin B (cas 1397-89-3) and Amphotericin B (cas 1397-89-3)-loaded microemulsion
Next:Research reportANTIMYCIN A (cas 1397-94-0)-induced mitochondrial dysfunction activates vagal sensory neurons via ROS-dependent activation of TRPA1 and ROS-independent activation of TRPV1)